ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS
Phase 2/3Active 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acquired Immune Deficiency Syndrome (AIDS)
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Trial Timeline
Jan 16, 2014 → Mar 1, 2027
NCT ID
NCT02016924About ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS is a phase 2/3 stage product being developed by Gilead Sciences for Acquired Immune Deficiency Syndrome (AIDS). The current trial status is active. This product is registered under clinical trial identifier NCT02016924. Target conditions include Acquired Immune Deficiency Syndrome (AIDS), HIV Infections.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02016924 | Phase 2/3 | Active |
Competing Products
20 competing products in Acquired Immune Deficiency Syndrome (AIDS)